Bristol-Myers Squibb Company (BMY) News
Follow Bristol-Myers Squibb Company (BMY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 149 public stories across 48 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Bristol Myers beats quarterly estimates, raises full-year sales outlook
Bristol Myers reported quarterly results above expectations and raised its full-year sales forecast, citing strong performance from new drugs.
EARNINGS | Oct 30, 2026, 01:48 AM UTC
M
Bristol Myers Squibb Reports Q3 2026 Revenue of $13.07B, EPS of $1.05
Revenue rose 6.9% year over year to $13.07 billion. Net income fell 1.5% to $2.16 billion, while diluted EPS declined 2.8% to $1.05.
EQUITY | Oct 29, 2026, 03:21 PM UTC
M
Bristol Myers Squibb Sees FY Adjusted Revenue at $49.75B-$50.25B
EARNINGS | Oct 29, 2026, 02:35 PM UTC
M
Bristol-Myers Squibb Reports Quarterly Results
The company reported results for the quarter ended September 30; no figures were provided.
EQUITY | Oct 29, 2026, 02:16 PM UTC
M
Bristol Myers Shares Rise 1.5% After Q3 Beat, 2026 Outlook Raise
Bristol Myers shares rose 1.5% after a third-quarter beat and a raised 2026 revenue outlook.
EARNINGS | Oct 29, 2026, 01:36 PM UTC
M
Bristol-Myers Squibb Cuts FY26 EPS Outlook, Raises Revenue Forecast
Bristol-Myers Squibb lowered its fiscal 2026 earnings outlook while raising its annual revenue forecast.
EARNINGS | Oct 29, 2026, 12:09 PM UTC
L
BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, L3Harris, Eli Lilly
BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, L3Harris, Eli Lilly Workspace search string for individual s
EQUITY | Oct 29, 2026, 11:42 AM UTC
M
Bristol Myers Squibb Q3 EPS Falls as Revenue Rises 7%
EQUITY | Oct 29, 2026, 11:33 AM UTC
M
Bristol Myers Squibb Raises 2026 Revenue Guidance
Bristol Myers Squibb raised its 2026 revenue guidance.
EARNINGS | Oct 29, 2026, 11:23 AM UTC
M
Bristol Myers Squibb Reports Third-Quarter Revenue of $13.07 Billion
EQUITY | Oct 29, 2026, 11:17 AM UTC
L
Bristol Myers Squibb Reports Third-Quarter Adjusted EPS of $1.35
EARNINGS | Oct 29, 2026, 11:14 AM UTC
M
Bristol Myers Raises 2026 Revenue Forecast, Cuts EPS Outlook on Charge
EARNINGS | Oct 29, 2026, 11:12 AM UTC
M
Bristol Myers Squibb Expects 2026 Adjusted EPS of $6.35-$6.55
Bristol Myers Squibb expects 2026 adjusted EPS of $6.35 to $6.55, versus a FactSet estimate of $6.34.
EARNINGS | Oct 29, 2026, 11:07 AM UTC
M
Bristol Myers cuts profit target despite new-drug momentum
Reuters reports that new medicines are boosting Bristol Myers, but the company has lowered its profit target.
EARNINGS | Oct 29, 2026, 11:04 AM UTC
M
Bristol Myers Squibb Sees FY Adjusted EPS of $6.35-$6.55
The outlook compares with an IBES estimate of $6.49.
EARNINGS | Oct 29, 2026, 11:04 AM UTC
M
Bristol Myers Squibb Sees FY Adjusted Revenue of $49.75B-$50.25B
The company’s fiscal-year adjusted revenue outlook is $49.75 billion to $50.25 billion, versus an IBES estimate of $49.89 billion.
EARNINGS | Oct 29, 2026, 11:04 AM UTC
M
Bristol Myers Squibb Reports Q3 Opdivo Revenue of $2.37 Billion
EQUITY | Oct 29, 2026, 11:03 AM UTC
L
Bristol Myers Squibb Reports Third-Quarter EPS of $1.05
EARNINGS | Oct 29, 2026, 10:59 AM UTC
M
Bristol Myers Squibb Sees Eliquis Revenue Rising 20%-25% in 2026
Bristol Myers Squibb still expects total worldwide Eliquis revenue to increase 20%-25% in 2026 versus a year earlier.
EARNINGS | Oct 29, 2026, 10:59 AM UTC
M
Bristol Myers Squibb’s 2026 adjusted EPS outlook includes net impact from acquired IPR&D charges and licensing
The 2026 adjusted EPS outlook range includes a net impact from acquired IPR&D charges and licensing income.
EARNINGS | Oct 29, 2026, 10:59 AM UTC
M
Bristol Myers Raises 2026 Revenue Forecast, Lowers EPS Outlook
Bristol Myers Squibb raised its full-year 2026 revenue forecast, citing strong sales of newer medicines, while lowering its 2026 earnings-per-share projection due to an acquisition-related charge.
EARNINGS | Oct 29, 2026, 10:59 AM UTC
M
Bristol Myers Squibb 3Q International Revenue Rises 3% to $4B
EARNINGS | Oct 29, 2026, 10:59 AM UTC
M
Bristol Myers Squibb 3Q U.S. Revenue Rises 9% to $9.07B
EARNINGS | Oct 29, 2026, 10:59 AM UTC
M
Bristol Myers Squibb 3Q Eliquis Revenue Rises 25% to $4.69B
EARNINGS | Oct 29, 2026, 10:59 AM UTC
M
Bristol Myers Squibb 3Q Legacy Portfolio Revenue Rose 1% to $5.42B
EARNINGS | Oct 29, 2026, 10:59 AM UTC
M
Bristol Myers Squibb 3Q Growth Portfolio Revenue Rises 12% to $7.66B
EARNINGS | Oct 29, 2026, 10:59 AM UTC
M
BMY Q3'26 Earnings Preview: EPS Estimate
Bristol-Myers Squibb is scheduled to report Q3'26 results on October 29 before the market opens. Revenue and EPS estimates were provided.
EQUITY | Oct 28, 2026, 11:01 AM UTC
M
Bristol-Myers Squibb Q3 Earnings Preview
Bristol-Myers Squibb is scheduled to report earnings Thursday before the bell. The preview cites the company’s $12.97 billion revenue last quarter, up 5.7% year over year.
EQUITY | Oct 28, 2026, 03:13 AM UTC
M
Hengrui Pharma Reports 88.9% Rise in Third-Quarter Profit
Hengrui Pharma reported an 88.9% rise in third-quarter 2026 profit, attributed in the headline to licensing deals.
EQUITY | Oct 27, 2026, 09:53 AM UTC
M
Hengrui Pharma registra alta de 88,9% no lucro do terceiro trimestre
A empresa atribuiu o aumento do lucro a acordos de licenciamento.
EARNINGS | Oct 27, 2026, 09:53 AM UTC
M
Cipla Misses Profit Targets as US Market Weakness Weighs
Cipla failed to meet its profit targets, citing weakness in the US market; its shares declined.
EARNINGS | Oct 27, 2026, 09:02 AM UTC
L
Cipla misses earnings expectations as shares fall
Cipla missed earnings expectations amid weak performance in the U.S. market, and its shares fell.
EARNINGS | Oct 27, 2026, 09:01 AM UTC
M
Cipla misses second-quarter profit view on muted US sales
Cipla missed its second-quarter profit view, with muted US sales cited.
EARNINGS | Oct 27, 2026, 08:17 AM UTC
M
China Approves Bayer Drug to Prevent Stroke
Bayer shares rose sharply after China approved its drug for stroke prevention.
REGULATION | Oct 26, 2026, 01:34 PM UTC
M
WuXi AppTec Q3 Net Profit Rises Nearly 1.4-Fold, Raises Guidance Again
WuXi AppTec says third-quarter net profit rose nearly 1.4 times year over year and it raised its full-year performance guidance again.
EQUITY | Oct 26, 2026, 09:46 AM UTC
M
WuXi AppTec Raises 2026 Outlook as Nine-Month Revenue Grows
WuXi AppTec said nine-month revenue rose, citing growth in its chemistry segment, and lifted its 2026 outlook.
EARNINGS | Oct 26, 2026, 09:27 AM UTC
M
Iza-Bren Doubles Median Progression-Free Survival in Phase 3 Lung Cancer Study
SystImmune said parent company Biokin reported positive results from a prespecified interim analysis of the PANKU-Lung01 study, comparing Iza-Bren with chemotherapy in previously treated EGFR-mutated non-small cell lung
EQUITY | Oct 26, 2026, 07:30 AM UTC
M
Patient Dies After Experimental Cell Therapy in Bristol Myers Squibb Study
Bristol Myers Squibb said a patient in its multiple sclerosis study died after receiving the experimental cell therapy. The patient developed movement-related problems after the infusion and died 44 days later. BMY share
EQUITY | Oct 23, 2026, 08:23 PM UTC
M
Bristol Myers Squibb Shares Fall 2% After Patient Death in MS Trial
Bristol Myers Squibb disclosed a patient death in its early-stage Breakfree-2 study of experimental CAR T therapy zolacabtagene autoleucel for multiple sclerosis. Its shares fell 2% on Friday.
EQUITY | Oct 23, 2026, 07:48 PM UTC
M
Bristol Myers Reports Patient Death in Early-Stage Cell Therapy Trial
Bristol Myers Squibb disclosed a patient death in an early-stage trial of its experimental CAR T-cell therapy. Its shares were down 2.5% in early trading.
EQUITY | Oct 23, 2026, 03:00 PM UTC
M
Tempus AI, Bristol Myers Sign Multi-Year Oncology Data and AI Deals
Tempus AI will license oncological data to Bristol Myers Squibb and provide access to its Lens platform under a multi-year agreement.
EQUITY | Oct 23, 2026, 02:17 PM UTC
M
Pathos AI Signs Multi-Year Deals With BMS and Tempus, Including $55M License
Pathos AI announced collaborations with Bristol Myers Squibb and Tempus AI, including a five-year, $55 million Tempus data license. BMS will lead a Series E financing and receive three-year exclusive rights to apply Path
EQUITY | Oct 23, 2026, 01:01 PM UTC
M
Bristol Myers Says IZA-BREN Cut Progression or Death Risk 59% in Phase 3
Bristol Myers said its breast cancer drug IZA-BREN reduced the risk of progression or death by 59% in a Phase 3 study.
EQUITY | Oct 23, 2026, 12:16 PM UTC
M
Bristol Myers Squibb Phase 3 Shows 59% Lower PFS Risk vs Chemotherapy
Izalontamab brengitecan reduced the risk of progression or death by 59% in HR+/HER2- breast cancer. Median progression-free survival was 8.2 months versus 4.0 months with chemotherapy (HR 0.41; p<0.0001); overall surviva
EQUITY | Oct 23, 2026, 11:53 AM UTC
M
Bloomsbury Reports Lower Interim Sales and Profits, Reaffirms Outlook
Revenue for the six months to 31 August fell to £151.6 million from £159.5 million a year earlier. The margin narrowed nearly four percentage points to 11.1%, and adjusted profit declined to £16.8 million from £24 millio
EARNINGS | Oct 22, 2026, 10:14 AM UTC
M
Bristol Myers Shares Fall About 3% After Mixed Lung Drug Trial Results
Shares fell roughly 3% in midday trading Monday after Bristol Myers Squibb reported mixed late-stage trial results in scarring lung disease: the lower dose succeeded, while the higher dose missed statistical significance
EARNINGS | Oct 12, 2026, 05:20 PM UTC
M
Bristol Myers Squibb’s Admilparant Meets Phase 3 Trial Primary Endpoint
Bristol Myers Squibb said its 52-week phase 3 trial of twice-daily admilparant in adults with idiopathic pulmonary fibrosis met its primary endpoint.
EQUITY | Oct 12, 2026, 11:28 AM UTC
M
Bristol Myers Squibb Says Phase 3 IPF Trial Met Primary Endpoint
Bristol Myers Squibb said its Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis met its primary endpoint.
EQUITY | Oct 12, 2026, 11:12 AM UTC
M
Bristol Myers Says Experimental Cancer Therapy Improved Progression-Free Survival
Bristol Myers Squibb said its experimental radiopharmaceutical therapy significantly improved progression-free survival in a late-stage study of patients with advanced rare gastrointestinal and pancreatic tumors whose di
EQUITY | Oct 12, 2026, 11:09 AM UTC
H
Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%
Bristol Myers Squibb & Co. (NYSE: BMY ) announced topline results from its Phase 3 EXCALIBER-RRMM study on Thursday. The pharmaceutical company revealed its drug Zenbexus (iberdomide) significantly reduced the risk of di
LIVE | Oct 08, 2026, 04:27 PM UTC
M
Bristol Myers Squibb's Camzyos Receives FDA Expanded Indication Approval
The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Bristol Myers Squibb's Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (OHCM) in adult and pediatric p
EQUITY | Sep 30, 2026, 10:42 PM UTC
M
Bristol Myers Squibb (BMY) Wins FDA OK to Expand CAMZYOS to Pediatric oHCM
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its drug CAMZYOS (mavacamten). The approval allows the drug to treat symptomatic obstructive hypertr
REGULATION | Sep 30, 2026, 09:32 PM UTC
M
FDA Approves First Drug For Rare Inherited Heart Condition in Children
The U.S. Food and Drug Administration has approved the first drug designed to improve symptoms in children suffering from a rare inherited heart condition.
EQUITY | Sep 30, 2026, 07:11 PM UTC
L
Major drugmakers turn to China for licensing deals
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-
GEOPOLITICS | Sep 30, 2026, 12:18 PM UTC
L
Summit soars after $2 billion investment from AstraZeneca for cancer therapies
Summit Therapeutics' NASDAQ:SMMT shares rose 23% in premarket trading on Tuesday after the drugmaker said AstraZeneca LSE:AZN would invest $2 billion in the company to test cancer treatments together.UK-listed shares of
EQUITY | Sep 29, 2026, 10:11 AM UTC
L
US drugmakers turn to China for licensing deals
Merck NYSE:MRK on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-developed medicines.
GEOPOLITICS | Sep 28, 2026, 02:31 PM UTC
L
Weekly Recap: ZDd raises MRD—negative CR in RRMM and Camzyos PDUFA
Bristol-Myers Squibb Company (NYSE:BMY) reported Phase 3 EXCALIBER—RRMM interim wins for ZDd over DVd in RRMM with higher MRD—negative CR and ORR but more neutropenia, awaits Sept. 30 FDA PDUFA on Camzyos for ages 12—17
GEOPOLITICS | Sep 28, 2026, 11:04 AM UTC
L
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals
Biotech and pharmaceutical investors have key U.S. Food and Drug Administration (FDA) events to watch this week, including decisions on treatments for a rare genetic disorder and a heart condition, while several other dr
REGULATION | Sep 28, 2026, 10:45 AM UTC
L
Bristol Myers Squibb (BMY) Doubles MRD—Negative CR to 41.1% in Phase 3 EXCALIBER-RRMM
Bristol Myers Squibb reported EXCALIBER-RRMM showed ZENBEXUS with daratumumab/dexamethasone achieved 41.1% MRD—negative CR vs 20.7% with DVd (p<0.0001) at 15.7 months’ median follow-up in 420 patients. PFS, the co—primar
NEWS | Sep 25, 2026, 02:01 PM UTC
L
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb (NYSE: BMY) today announced first time presentation of results from the prespecified analysis of the pivotal Phase 3 EXCALIBER-RRMM trial (NCT04975997) evaluating ZENBEXUS™ (iberdomide) in combinatio
NEWS | Sep 25, 2026, 02:00 PM UTC